Britannia Life Sciences Inc.
BLSIF
$0.06
$0.03100.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.03% | -92.96% | -93.37% | -93.38% | -95.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.03% | -92.96% | -93.37% | -93.38% | -95.12% |
| Cost of Revenue | -28.78% | 117.33% | -19.95% | -52.74% | -69.62% |
| Gross Profit | 170.67% | -212.85% | -122.56% | -107.55% | -103.37% |
| SG&A Expenses | -24.20% | 41.86% | 16.77% | -31.93% | -39.91% |
| Depreciation & Amortization | 4.85% | 37.42% | 104.61% | 310.28% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.45% | -17.00% | -29.30% | -53.41% | -60.33% |
| Operating Income | 33.07% | -199.11% | -1,445.71% | -734.65% | -264.35% |
| Income Before Tax | 398.16% | 454.08% | -63.39% | -1,214.49% | -391.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 387.07% | 391.95% | -59.33% | -2,328.18% | -475.31% |
| Earnings from Discontinued Operations | -86.58% | 1,409.60% | 1,751.61% | 4,588.70% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 146.51% | 124.38% | -147.27% | -251.63% |
| Net Income | 106.85% | 345.83% | 205.41% | 228.35% | 243.61% |
| EBIT | 33.07% | -199.11% | -1,445.71% | -734.65% | -264.35% |
| EBITDA | 34.15% | -210.58% | -3,669.31% | -520.54% | -237.54% |
| EPS Basic | 107.03% | 346.01% | 205.41% | 228.05% | 243.58% |
| Normalized Basic EPS | 47.86% | -41.94% | -102.82% | -17,800.00% | -638.46% |
| EPS Diluted | 107.03% | 346.01% | 205.41% | 228.05% | 243.58% |
| Normalized Diluted EPS | 47.86% | -41.94% | -102.82% | -17,800.00% | -638.46% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |